Notification That Annual Report Will Be Submitted Late (nt 10-k)
31 Março 2020 - 7:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
|
|
OMB
APPROVAL
|
|
FORM
12b-25
|
OMB
Number: 3235-0058
Expires:
February 28, 2022 Estimated average burden hours per response............. 2.50
|
|
NOTIFICATION
OF LATE FILING
|
SEC
FILE NUMBER
001-37428
|
|
|
CUSIP
NUMBER
|
(Check
one):
|
[X]
Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ]
Form N-SAR [ ] Form N-CSR
|
|
For
the period ending December 31, 2019
|
|
|
|
|
[ ]
|
Transition
Report on Form 10-K
|
|
[ ]
|
Transition
Report on Form 20-F
|
|
[ ]
|
Transition
Report on Form 11-K
|
|
[ ]
|
Transition
Report on Form 10-Q
|
|
[ ]
|
Transition
Report on Form N-SAR
|
|
|
|
|
For
the Transition Period Ended ________________________
|
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
|
|
Ritter
Pharmaceuticals, Inc.
|
Full
Name of Registrant
|
|
N/A
|
Former
Name if Applicable
|
|
1880
Century Park East, Suite 1000
|
Address
of Principal Executive Office (Street and Number)
|
|
Los
Angeles, California 90067
|
City,
State and Zip Code
|
PART
II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate).
[X]
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof,
will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III - NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
The
Registrant was unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the
“Annual Report”) by the prescribed deadline without incurring undue hardship and expense, due to unexpected difficulties
and delays in obtaining certain stock-related information from the Registrant’s transfer agent, which is in the process
of transitioning its records in connection with its recent acquisition, and certain logistical difficulties encountered as a result
of the Governor of California’s recent “shelter in place” order. The Registrant expects to file the Annual Report
on March 31, 2020, but in any event within the fifteen calendar day extension provided by Rule 12b-25.
PART
IV - OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
|
|
|
|
John
W. Beck
|
|
(858)
|
|
205-9902
|
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If answer is no, identify report(s).
|
[X]
Yes [ ] No
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal
year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
[ ]
Yes [X] No
|
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
|
RITTER
PHARMACEUTICALS, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 31, 2020
|
By:
|
/s/
John W. Beck
|
|
|
John
W. Beck
|
|
|
Chief
Financial Officer
|
Ritter Pharmaceuticals (NASDAQ:RTTR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Ritter Pharmaceuticals Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Ritter Pharmaceuticals Inc